最新公告列表 《天臣医疗2025年年度业绩预告》 近日，天臣国际医疗科技股份有限公司披露《2025年年度业绩预告》。公告显示，公司预计2025年年度 实现归属于母公司所有者的净利润同比增加3,100.00万元到3,700.00万元，同比增长59.74%到71.30%； 扣除非经常性损益后的净利润同比增加2,700.00万元到3,100.00万元，增长57.77%到66.32%。业绩增长 主要得益于腔镜吻合器类产品销售收入稳定增长及汇兑收益增加。本次业绩预告未经注册会计师审计， 具体数据以正式披露的2025年年度报告为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年1月30日收盘，天臣医疗（688013）报收于42.8元，较前一交易日上涨1.18%，最新总市值为 34.73亿元。该股当日开盘42.08元，最高43.06元，最低41.8元，成交额达4982.63万元，换手率为 1.45%。 ...

Core Viewpoint - Bluefan Medical (002382) is expected to report a significant increase in net loss for the fiscal year 2025, primarily due to various operational challenges and financial adjustments [1] Group 1: Financial Performance - As of January 30, 2026, Bluefan Medical's stock closed at 5.92 yuan, with a market capitalization of 5.962 billion yuan [1] - The company anticipates a net loss attributable to shareholders ranging from 650 million yuan to 850 million yuan for 2025, which represents an increase in losses compared to the previous year [1] - The health protection division is facing order fluctuations and price pressures due to international trade conditions, contributing to the expected losses [1] Group 2: Specific Loss Drivers - The cardiovascular division incurred a fair value loss of approximately 120 million yuan due to valuation changes in its associate company, Suzhou Tongxin [1] - The company headquarters has recognized financial expenses related to financial liabilities amounting to 100 million yuan [1] - Despite the overall losses, the cardiovascular division is expected to achieve operational profitability, excluding non-operating items [1]

证券日报网讯 1月30日，赛诺医疗发布公告称，公司预计2025年营业收入为51，940万元至52，600万 元，同比增长13%至15%；归属于上市公司股东的净利润为4，300万元至5，000万元，同比增长2， 767%至3，233%。 （编辑 丛可心） ...

证券日报网讯1月30日，东方生物在互动平台回答投资者提问时表示，公司产品境外销售占比较高，主 要覆盖美国、欧洲等区域，公司销售采取经销为主、直销为辅的销售模式，以"东方基因""美国衡健"自 主品牌销售为主、辅以ODM方式销售。 ...

Group 1 - The core viewpoint of the article highlights that Xinhua Medical has focused its R&D expenses over the past three years on two main areas: medical devices and pharmaceutical equipment [1] - The company is pursuing core technology breakthroughs and product innovations in high-end, intelligent, and green directions, particularly in high-end radiotherapy and imaging equipment, infection control devices, minimally invasive surgical instruments and consumables, and high-end pharmaceutical formulation equipment [1] - Additionally, Xinhua Medical is expanding into cutting-edge areas such as rehabilitation intelligent equipment, continuously advancing product technology upgrades and international certifications to strengthen its core technological barriers [1]

《振德医疗2026年第二次临时股东会会议材料》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近日，振德医疗披露《2026年第二次临时股东会会议材料》，拟对第二期员工持股计划（草案）及其管 理办法进行修订，明确未解锁股份由公司回购注销，并修订持有人权益处置方式。同时，公司拟回购第 二期员工持股计划未解锁的1,829,868股股份，回购价格为22.17元/股。此外，拟将已回购但未使用的 129,442股及上述拟回购股份合计1,959,310股用途变更为注销，公司总股本将由265,835,535股减少至 263,876,225股，并相应修改公司章程，办理工商变更登记。 最新公告列表 截至2026年1月30日收盘，振德医疗（603301）报收于68.77元，较前一交易日上涨2.87%，最新总市值 为182.82亿元。该股当日开盘66.85元，最高68.84元，最低66.17元，成交额达1.39亿元，换手率为 0.77%。 ...

Group 1 - The core viewpoint of the article is that Weili Medical anticipates a 10% higher unit production cost at its Indonesian factory compared to domestic production [1] - Customers are currently offering prices for products shipped from Indonesia that exceed those for domestic products, which is expected to cover the increased production costs [1] - After the official launch of the Indonesian factory, the company plans to negotiate product prices with customers based on actual production costs while maintaining existing gross margin levels [1] - The transfer of production to Indonesia is not expected to significantly impact the company's product gross margins [1]

（编辑 王雪儿） 证券日报网讯 1月30日，新华医疗在互动平台回答投资者提问时表示，公司在安哥拉的相关订单金额正 在稳步增长，直线加速器等高端设备产品正在与安哥拉当地医疗机构保持深度沟通，积极推进市场开发 工作。 ...

业绩显著改善主要由三大因素推动：一是多款旗舰产品的国内销售持续强劲增长，包括麒麟血流导向装 置、神经血管导丝、UltraFree药物洗脱PTA球囊扩张导管及Swan静脉腔内射频闭合导管；二是国际销售 同比增长超过100%；三是相对稳定的毛利率加上持续提升的运营效率。 近日，归创通桥发布公告称，预计截至2025年公司权益持有人应占溢利净额将超过2.4亿元，较截至 2024年12月31日止年度的1亿元同比增长约139.4%。同时，集团收入预期将超过10.5亿元，较截至2024 年12月31日止年度的7.8亿元同比增加约34.6%。 ...

Group 1 - The company, Aihuilong, announced an expected net profit attributable to shareholders of the parent company for the year 2025 to be between 20 million and 30 million yuan, representing a year-on-year decrease of 90.05% to 93.37% [1]